保肝药在预防与治疗抗结核药所致肝损伤中的利用分析  

Analysis of the Utilization of Hepatoprotective Agents in Prevention and Treatment of Anti-tuberculosis Drugs Induced Liver Damage

作　　者：赵良义[1] 邵艳新[1] 董书梅[1] 郭雁[1] 李国兴[1] 

机构地区：[1]河北省胸科医院药学部,石家庄市050041

出　　处：《中国药房》2011年第10期877-881,共5页China Pharmacy

摘　　要：目的:了解保肝药在预防与治疗抗结核药所致的肝损伤中的应用现状及趋势。方法:对我院2005-2009年在预防和治疗抗结核药引起的肝损伤中应用的保肝药的品种、用药数量、销售金额、用药频度(DDDS)、日均费用(DDC)等进行统计、分析。结果:我院所应用的保肝药涉及24个品种,5年间销售金额增长了280%,总DDDs增长了195%;注射用还原型谷胱甘肽、硫普罗宁注射液连续5年进入销售金额的前3名;葡醛内酯片的DDDs连续5年排第1位,注射用还原型谷胱甘肽的DDDs增加了265%,中成药的DDDs增长了259%。结论:保肝药在预防和治疗抗结核药引起的肝损伤中的应用呈明显的上升趋势。OBJECTIVE： To study the current situation and tendency of the utilization of hepatoprotective agents in the preven- tion and treatment of anti-tuberculosis induced liver damage. METHODS： The utilization of hepatoprotective agents in the preven- tion and treatment of anti-tuberculosis induced liver damage in our hospital from 2005 to 2009 were analyzed statistically in respect of variety, amount, consumption sun, DDDs and DDC. RESULTS ： Hepatoprotective agents used in our hospital involved 24 variet- ies. The consumption sum and DDDs of drugs increased by 280% and 195% during five years. The consumption sum of Reduced glutathione for injection and Tiopronin Injection were in the top 3 place during five years. Glucurolactone tablets took up the first place in the list of DDDs during five years. DDDs of Reduced glutathione for injection and Chinese patent medicine increased by 265% and 259% respectively during five years. CONCLUSION： Hepatoprotective agents show a rising trend in the prevention and treatment of anti-tuberculosis drugs induced liver damage.

关 键 词：保肝药 抗结核药 肝损伤 利用分析 

分 类 号：R969.3[医药卫生—药理学] R978.3[医药卫生—药学]